Royal Bank Of Canada Eli Lilly & CO Call Options Transaction History

Royal Bank Of Canada

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$772.14 - $960.02 $38.6 Million - $48 Million	50,000 New	50,000 $44.3 Million
Q3 2022 Nov 14, 2022	BUY	$296.48 - $337.87 $3.5 Million - $3.99 Million	11,800 Added 45.21%	37,900 $12.3 Million
Q2 2022 Aug 15, 2022	SELL	$278.73 - $327.27 $3.73 Million - $4.39 Million	-13,400 Reduced 33.92%	26,100 $8.46 Million
Q1 2022 May 16, 2022	BUY	$234.69 - $291.66 $5.66 Million - $7.03 Million	24,100 Added 156.49%	39,500 $11.3 Million
Q3 2021 Nov 15, 2021	BUY	$221.6 - $272.71 $3.41 Million - $4.2 Million	15,400 New	15,400 $3.56 Million

4,031

739M

8.27M

10.5M

Ticker LLY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 950,174,976
Market Cap $728B
Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.